ELI LILLY & Co 4

Director Ralph Alvarez received a small, routine stock unit award (about $1.1K of Eli Lilly common stock equivalents) in lieu of cash compensation under the directors’ deferral plan.

On July 20, 2026, director Ralph Alvarez of Eli Lilly & Co elected to defer cash compensation into stock units, resulting in an award of approximately 106 stock units (based on a reference price of $10.8263 per share, for a total of about $1,146.90) under the Lilly Directors' Deferral Plan, to be settled in common stock after his separation from service. This is a routine compensation-related acquisition (coded 'A') rather than an open-market purchase, and the resulting units are reflected as directly owned, increasing his beneficial interest to about 55,734.2935 shares of common stock equivalents, plus an additional 758 shares held indirectly by trust. Using the current stock price of about $1,173.80, his direct holdings are worth roughly $65 million, while he disclaims beneficial ownership of certain reported securities beyond his pecuniary interest.

Filing Facts

CIK

59478

Ticker

LLY

Form

4

Source Type

fda

Accession

0001310215-26-000013

Alert Tier

4